Oric
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
240 E Grand Ave Fl 2, South San Francisc...Phone Number
(650) 388-5600Website
www.oricpharma.comRevenue
-Stock Symbol
ORICIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About Oric
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. ORIC's lead program, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to treatment resistance to multiple classes of anti-cancer therapeutics across a variety of solid tumors. ORIC's pipeline also includes an orally bioavailable small molecule inhibitor of CD73, as well as other undisclosed programs targeting mechanisms of oncology therapeutic resistance. ORIC is funded by biotechnology investors and is headquartered in South San Francisco, California.Explore more
Oric Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oric your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Oric is spiking on competitors!
Funding: Get notified immidiatlly once Oric has new funding data
Click to see if Oric had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Oric
Earning: See what the market has to say on Oric recently announced quarterly report
Oric, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Oric has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Oric launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Oric
Compare insights from companies similar to Oric, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oric is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oric is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oric.
Oric financials insights
Gather financial insights about Oric, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$15M
2015
Series B
$53M
2018
Series C
$50M
2019
Series D
$55M
2023
Share Placement
$85M
2025
Stock/Share Issuance
$125M
Oric Tech Stack
A closer look at the technologies used by Oric
See more technologies
Most Recent Scoops
Person-Based
Events
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Events, Finance, Investor Relations
Open Position
Open Position
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oric
Sign Up For FreeTo access detailed company insights
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. ORIC's lead program, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to treatment resistance to multiple classes of anti-can... Read More
